Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena

ABSTRACT: Proteomics analysis of matched tumor and normal adjacent tumor regions of 40 patients with multiparametric magnetic resonance imaging (mpMRI) visible or invisible tumors. All patients have clinically significant intermediate-risk (pathological ISUP Grade Group 2), localized prostate cancer.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Dr. Thomas Kislinger

PROVIDER: MSV000088000 | MassIVE | Wed Aug 18 11:14:00 BST 2021

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Neoadjuvant Intense ADT for High Risk Prostate Cancer: Baseline Analysis

Project description:The purpose of this study was to develop better ways of detecting prostate cancer before and after pre-operative treatment, and to test the feasibility of multi parametric magnetic resonance imaging (mpMRI) for the localization and detection of focal prostate cancer both before and after pre-operative treatment with ADT and enzalutamide. In this study, patients with intermediate and high risk prostate cancer received six months of neoadjuvant intense androgen deprivation therapy prior to radical prostatectomy. Biopsies were acquired prior to treatment. Tissue from biopsy and radical prostatectomy were subjected to sequencing and analysis for determination of features associated with response or resistance to treatment.

2025-08-21 | GSE152516 | GEO

Proteomic and phosphoproteomic analysis of prostate cancer

Project description:The present study had a total of 125 primary prostate cancer samples collected with paired non-tumor adjacent lung tissues from the treatment-naïve Chinese patients and proteogenomic analysis was performed.

2024-02-07 | PXD049446 |

Prostate cancer progression: From non-malignant to bone metastasisProstate cancer progression: From non-malignant to bone metastasis

Project description:Proteome characterization of gland confined prostate tumors and non-malignant prostate tissue. Whole cell protein extracts were purified from FFPE radical prostatectomy specimens for a total of 28 tumor samples and 8 adjacent non-malignant prostate tissues. Associated ProteomeXchange identifiers: PXD003430, PXD003452, PXD003515, PXD004132, PXD003615, PXD003636. Quantitative proteomic analysis of adjacent non-malignant prostate tissue (n=8) and gland confined prostate tumors (n=28) obtained from radical prostatectomy procedures; and bone metastatic prostate tumors (n=22) obtained from patients operated to relief spinal cord compression. At the time of surgery, most metastatic patients had relapsed after androgen-deprivation therapy, while 5 were previously untreated.

2018-08-21 | PXD009868 | Pride

The Proteogenomic Landscape of Curable Prostate Cancer

Project description:Proteogenomic analysis of 76 patients with clinically relevant intermediate-risk, localized prostate cancer.

| MSV000081552 | MassIVE

Imaging Studies of Local Responses of Prostate Cancer to Radiation Therapy

Project description:Patients receiving radiation therapy for prostate cancer received a multiparametric MRI and MRI/ultrasound-fusion targeted biopsy. Patients received a second mpMRI six months after radiation therapy. The goal of this study was to generate gene expression profiles of prostate cancer tumor tissue prior to treatment, and compare the gene expression profiles of those patients based on imaging response or time to biochemical recurrence.

2025-08-25 | GSE129274 | GEO

Expression data from LCM captured prostate cancer cells

Project description:The prostate represents a complex mix of cell types and there is a need to analyze distinct cell populations to better understand their potential interactions. This study of cell-type specific gene expression patterns will contribute to understanding of how tumor epithelial cells may be affected by adjacent interstitial stromal cells within the tumor microenvirnonment. LCM and microarray analysis were used to identify gene expression patterns in prostate cancer epithelial and interstitial stromal cell populations. More than 500 genes whose expression levels were significantly different in epithelial cells versus adjacent stromal tissue were identified. Several chemokines and growth factors were more highly expressed in prostate cancer stromal cells while several transcription factors and receptors were more highly expressed in epithelial cells. Five micron serial sections from three different intermediate grade prostate tumors were provided. One section from each had been stained by hematoxylin and eosin and the tumor areas marked for identification. To obtain RNA from 2 different tissue types (glandular epithelium and interstitial stroma) tumor areas observed to have abundant cells of interest were identified. Tumor epithelium and adjacent stromal tissue were collected separately from each slide. We sought to obtain similar populations of cells of each tissue type, so to that end, we examined each slide and and marked areas to direct the laser capture. Approximately 1,000 cells were captured per cap and RNA was extracted and hybridized to Affymetrix microarrays as recommended by manufacturer.

2010-04-10 | E-GEOD-20758 | biostudies-arrayexpress

Prostate miRNA expression profiles

Project description:Comparison of miRNA expression profiles in normal and malignant prostate tissues. Keywords: microarray analysis of microRNA expression profiles MicroRNA expression was compared between normal prostate tissue from either young subjects that died of trauma, or normal adjacent to tumor, and prostatic tumors in older prostate cancer patients. RNA was isolated from frozen tissue sections, enriched for the miRNA fraction, which was subsequently labeled and hybridized to miRNA microarrays for expression profiling analysis.

2010-05-14 | E-GEOD-6636 | biostudies-arrayexpress

The proteome of localized prostate cancer, part 3

2016-08-18 | MSV000080070 | MassIVE

The proteome of localized prostate cancer, part 5

2016-08-18 | MSV000080067 | MassIVE

The proteome of localized prostate cancer, part 4

2016-08-18 | MSV000080068 | MassIVE